Nonreceptor tyrosine kinases in prostate cancer

Yu Ming Chang, Hsing Jien Kung, Christopher P. Evans

Research output: Contribution to journalReview article

92 Citations (Scopus)

Abstract

BACKGROUND: Carcinoma of the prostate (CaP) is the most commonly diagnosed cancer in men in the United States. Signal transduction molecules such as tyrosine kinases play important roles in CaP. Src, a nonreceptor tyrosine kinase (NRTK) and the first proto-oncogene discovered is shown to participate in processes such as cell proliferation and migration in CaP. Underscoring NRTK's and, specifically, Src's importance in cancer is the recent approval by the US Food and Drug Administration of dasatinib, the first commercial Src inhibitor for clinical use in chronic myelogenous leukemia (CML). In this review we will focus on NRTKs and their roles in the biology of CaP. MATERIALS AND METHODS: Publicly available literature from PubMed regarding the topic of members of NRTKs in CaP was searched and reviewed. RESULTS: Src, FAK, JaK1/2, and ETK are involved in processes indispensable to the biology of CaP: cell growth, migration, invasion, angiogenesis, and apoptosis. CONCLUSIONS: Src emerges as a common signaling and regulatory molecule in multiple biological processes in CaP. Src's relative importance in particular stages of CaP, however, required further definition. Continued investigation of NRTKs will increase our understanding of their biological function and potential role as new therapeutic targets.

Original languageEnglish
Pages (from-to)90-100
Number of pages11
JournalNeoplasia
Volume9
Issue number2
DOIs
Publication statusPublished - Jan 1 2007
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Prostate
Prostatic Neoplasms
Carcinoma
Cell Movement
Biological Phenomena
Proto-Oncogenes
United States Food and Drug Administration
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PubMed
Signal Transduction
Neoplasms
Cell Proliferation
Apoptosis
Growth

Keywords

  • ETK
  • FAK
  • Nonreceptor tyrosine kinase
  • Prostate cancer
  • Src

ASJC Scopus subject areas

  • Cancer Research

Cite this

Nonreceptor tyrosine kinases in prostate cancer. / Chang, Yu Ming; Kung, Hsing Jien; Evans, Christopher P.

In: Neoplasia, Vol. 9, No. 2, 01.01.2007, p. 90-100.

Research output: Contribution to journalReview article

Chang, Yu Ming ; Kung, Hsing Jien ; Evans, Christopher P. / Nonreceptor tyrosine kinases in prostate cancer. In: Neoplasia. 2007 ; Vol. 9, No. 2. pp. 90-100.
@article{53db2e45a1844a97ba90c441b4c829a9,
title = "Nonreceptor tyrosine kinases in prostate cancer",
abstract = "BACKGROUND: Carcinoma of the prostate (CaP) is the most commonly diagnosed cancer in men in the United States. Signal transduction molecules such as tyrosine kinases play important roles in CaP. Src, a nonreceptor tyrosine kinase (NRTK) and the first proto-oncogene discovered is shown to participate in processes such as cell proliferation and migration in CaP. Underscoring NRTK's and, specifically, Src's importance in cancer is the recent approval by the US Food and Drug Administration of dasatinib, the first commercial Src inhibitor for clinical use in chronic myelogenous leukemia (CML). In this review we will focus on NRTKs and their roles in the biology of CaP. MATERIALS AND METHODS: Publicly available literature from PubMed regarding the topic of members of NRTKs in CaP was searched and reviewed. RESULTS: Src, FAK, JaK1/2, and ETK are involved in processes indispensable to the biology of CaP: cell growth, migration, invasion, angiogenesis, and apoptosis. CONCLUSIONS: Src emerges as a common signaling and regulatory molecule in multiple biological processes in CaP. Src's relative importance in particular stages of CaP, however, required further definition. Continued investigation of NRTKs will increase our understanding of their biological function and potential role as new therapeutic targets.",
keywords = "ETK, FAK, Nonreceptor tyrosine kinase, Prostate cancer, Src",
author = "Chang, {Yu Ming} and Kung, {Hsing Jien} and Evans, {Christopher P.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1593/neo.06694",
language = "English",
volume = "9",
pages = "90--100",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Nonreceptor tyrosine kinases in prostate cancer

AU - Chang, Yu Ming

AU - Kung, Hsing Jien

AU - Evans, Christopher P.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - BACKGROUND: Carcinoma of the prostate (CaP) is the most commonly diagnosed cancer in men in the United States. Signal transduction molecules such as tyrosine kinases play important roles in CaP. Src, a nonreceptor tyrosine kinase (NRTK) and the first proto-oncogene discovered is shown to participate in processes such as cell proliferation and migration in CaP. Underscoring NRTK's and, specifically, Src's importance in cancer is the recent approval by the US Food and Drug Administration of dasatinib, the first commercial Src inhibitor for clinical use in chronic myelogenous leukemia (CML). In this review we will focus on NRTKs and their roles in the biology of CaP. MATERIALS AND METHODS: Publicly available literature from PubMed regarding the topic of members of NRTKs in CaP was searched and reviewed. RESULTS: Src, FAK, JaK1/2, and ETK are involved in processes indispensable to the biology of CaP: cell growth, migration, invasion, angiogenesis, and apoptosis. CONCLUSIONS: Src emerges as a common signaling and regulatory molecule in multiple biological processes in CaP. Src's relative importance in particular stages of CaP, however, required further definition. Continued investigation of NRTKs will increase our understanding of their biological function and potential role as new therapeutic targets.

AB - BACKGROUND: Carcinoma of the prostate (CaP) is the most commonly diagnosed cancer in men in the United States. Signal transduction molecules such as tyrosine kinases play important roles in CaP. Src, a nonreceptor tyrosine kinase (NRTK) and the first proto-oncogene discovered is shown to participate in processes such as cell proliferation and migration in CaP. Underscoring NRTK's and, specifically, Src's importance in cancer is the recent approval by the US Food and Drug Administration of dasatinib, the first commercial Src inhibitor for clinical use in chronic myelogenous leukemia (CML). In this review we will focus on NRTKs and their roles in the biology of CaP. MATERIALS AND METHODS: Publicly available literature from PubMed regarding the topic of members of NRTKs in CaP was searched and reviewed. RESULTS: Src, FAK, JaK1/2, and ETK are involved in processes indispensable to the biology of CaP: cell growth, migration, invasion, angiogenesis, and apoptosis. CONCLUSIONS: Src emerges as a common signaling and regulatory molecule in multiple biological processes in CaP. Src's relative importance in particular stages of CaP, however, required further definition. Continued investigation of NRTKs will increase our understanding of their biological function and potential role as new therapeutic targets.

KW - ETK

KW - FAK

KW - Nonreceptor tyrosine kinase

KW - Prostate cancer

KW - Src

UR - http://www.scopus.com/inward/record.url?scp=33847306882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847306882&partnerID=8YFLogxK

U2 - 10.1593/neo.06694

DO - 10.1593/neo.06694

M3 - Review article

C2 - 17357254

AN - SCOPUS:33847306882

VL - 9

SP - 90

EP - 100

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 2

ER -